VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO GI 2023 | PANAMA: addition of maintenance panitumumab does not affect QoL in mCRC

Alexej Ballhausen, MD, Charité, Berlin, Germany, shares health-related quality of life (QoL) results of patients enrolled in the randomized PANAMA trial (NCT01991873), which evaluated fluorouracil and folinic acid with or without panitumumab as maintenance therapy following first-line panitumumab and FOLFOX alone in RAS wild-type metastatic colorectal cancer (mCRC). Addition of panitumumab in the maintenance setting significantly improved progression free-survival and did not impact QoL. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter